On November 27, 2020, the National Committee for the evaluation of medical devices and health technologies (CNEDiMTS) at the French National Authority for Health (HAS) posted a decision about the registration of flash self-monitoring glucose system FREESTYLE LIBRE 2 in the LPPR list.
FREESTYLE LIBRE 2 by Abbott received sufficient Actual Benefit (SA) for the measurement of interstitial glucose, in addition to self-monitoring of blood glucose in patients with type 1 or type 2 diabetes (adults and children more than four years) treated with intensified insulin therapy (by external pump more than or equal to 3 injections per day). Clinical Added Value (ASA) of FREESTYLE LIBRE 2 was estimated at level IV (minor improvement) compared to FREESTYLE LIBRE.
The full details in French can be found here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).